IN

Inspire Medical Systems, Inc.

INSPHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$912.0M
+13.6% YoY
Net Income
$145.4M
+171.8% YoY
EBITDA
$79.8M
+22.7% YoY
Free Cash Flow
$94.6M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 31 MACD Negative CrossoverHistogram -0.1520, negative momentum
Aug 29 MACD Negative CrossoverHistogram -0.1520, negative momentum
About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the. The company carries a $1.80B market cap, placing it firmly in the small-cap category. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA.

Where INSP stands vs its 150-day and 200-day moving averages

As of the August 31, 2026 close, INSP finished 13.57% above its 150-day moving average ($54.10) and 8.05% below its 200-day moving average ($66.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is INSP overbought or oversold?

At the August 31, 2026 close, INSP's RSI(14) was 57.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.80B
P/E (TTM)13.72
Fwd P/E40.43
EPS$4.53
Beta0.70
52W Change-22.6%
ROE18.0%
Analysis

With $320.7M in cash and $29.1M in debt, INSP maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $94.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 18.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.9% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $407.9M (2022) to $912.0M (2025), reflecting a 124% increase over the period.

With cash comfortably exceeding debt, INSP has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Inspire Medical Systems, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms